Curriculum Vitae Michalis (Michael) V. Karamouzis - MyLoyalCard

2) E.G. Iliopoulou, M.V. Karamouzis, et al.: “Characterization of a subset of CD4+ T
cells expressing CD161 in cancer patients and healthy individuals”, 42 th ASCO
Annual Meeting, Atlanda, Giorgia, U.S.A., June 2-6, 2006.
3) M.V. Karamouzis, et al.: “Phase II trial of pemetrexed (P) and bevacizumab (B) in
patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma
(HNSCC): an interim analysis”, 43 th ASCO Annual Meeting, Chicago, Illinois,
U.S.A., June 1-5, 2007.
4) R. Smith, M.V. Karamouzis, et al.: “Phase I trial of pemetrexed (P) in
combination with cetuximab (C) and concurrent radiotherapy (RT) in patients
(pts) with head and neck cancer (HNC)”, 43 th ASCO Annual Meeting, Chicago,
Illinois, U.S.A., June 1-5, 2007.
5) J. Johnson, S. Agarwala, M.V. Karamouzis, et al.: “Phase III randomized trial of
postoperative radiotherapy (RT) with or without carboplatin (Cb) in patients (pts)
with head and neck squamous cell carcinoma (HNSCC)”, 43 th ASCO Annual
Meeting, Chicago, Illinois, U.S.A., June 1-5, 2007.
6) D.E. Heron, R.L. Ferris, S. Burton, S. Lai, M.V. Karamouzis, et al.: “Phase I dose
escalation study of fractionated stereotactic radiosurgery (fSRS) for recurrent
squamous cell carcinoma of the head and neck (SCCHN)”, 43 th ASCO Annual
Meeting, Chicago, Illinois, U.S.A., June 1-5, 2007.
7) Argiris, M.V. Karamouzis, et al.: “Phase II trial of docetaxel (T), cisplatin (P), and
cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced
head and neck squamous cell carcinoma (HNSCC), 43 th ASCO Annual Meeting,
Chicago, Illinois, U.S.A., June 1-5, 2007.
8) M. Gibson, M.V. Karamouzis, et al.: “Phase I trial of pemetrexed in combination
with cetuximab and concurrent radiotherapy in head and neck cancer (HNC), 49 th
ASTRO Annual Meeting, Los Angeles, California, U.S.A., October 28-November
1, 2007.
9) S.C. Buch, M.V. Karamouzis, et al.: “Gene expression signatures correlate with
survival of patients with head and neck cancer treated with platinum-based
regimens”, AACR Annual Meeting, San Diego, California, U.S.A., April 12-16,
2008.
10) T. Feinstein, L. Raez, K. Rajasenan, M. Gibson, P. Savvides, M.V. Karamouzis, et
al.: “Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or
11
11